Brain Targeting Delivery Facilitated by Ligand-Functionalized Layered Double Hydroxide Nanoparticles
A delivery platform with highly selective permeability through the blood-brain barrier (BBB) is essential for brain disease treatment. In this research, we designed and prepared a novel target nanoplatform, that is, layered double hydroxide (LDH) nanoparticle conjugated with targeting peptide-ligand...
Uloženo v:
| Vydáno v: | ACS applied materials & interfaces Ročník 10; číslo 24; s. 20326 |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
20.06.2018
|
| Témata: | |
| ISSN: | 1944-8252, 1944-8252 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | A delivery platform with highly selective permeability through the blood-brain barrier (BBB) is essential for brain disease treatment. In this research, we designed and prepared a novel target nanoplatform, that is, layered double hydroxide (LDH) nanoparticle conjugated with targeting peptide-ligand Angiopep-2 (Ang2) or rabies virus glycoprotein (RVG) via intermatrix bovine serum albumin for brain targeting. In vitro studies show that functionalization with the target ligand significantly increases the delivery efficiency of LDH nanoparticles to the brain endothelial (bEnd.3) cells and the transcytosis through the simulated BBB model, that is, bEnd.3 cell-constructed multilayer membrane. In vivo confocal neuroimaging of the rat's blood-retina area dynamically demonstrates that LDH nanoparticles modified with peptide ligands have shown a prolonged retention period within the retina vessel in comparison with the pristine LDH group. Moreover, Ang2-modified LDH nanoparticles are found to more specifically accumulate in the mouse brain than the control and RVG-modified LDH nanoparticles after 2 and 48 h intravenous injection. All these findings strongly suggest that Ang2-modified LDHs can serve as an effective targeting nanoplatform for brain disease treatment. |
|---|---|
| AbstractList | A delivery platform with highly selective permeability through the blood-brain barrier (BBB) is essential for brain disease treatment. In this research, we designed and prepared a novel target nanoplatform, that is, layered double hydroxide (LDH) nanoparticle conjugated with targeting peptide-ligand Angiopep-2 (Ang2) or rabies virus glycoprotein (RVG) via intermatrix bovine serum albumin for brain targeting. In vitro studies show that functionalization with the target ligand significantly increases the delivery efficiency of LDH nanoparticles to the brain endothelial (bEnd.3) cells and the transcytosis through the simulated BBB model, that is, bEnd.3 cell-constructed multilayer membrane. In vivo confocal neuroimaging of the rat's blood-retina area dynamically demonstrates that LDH nanoparticles modified with peptide ligands have shown a prolonged retention period within the retina vessel in comparison with the pristine LDH group. Moreover, Ang2-modified LDH nanoparticles are found to more specifically accumulate in the mouse brain than the control and RVG-modified LDH nanoparticles after 2 and 48 h intravenous injection. All these findings strongly suggest that Ang2-modified LDHs can serve as an effective targeting nanoplatform for brain disease treatment.A delivery platform with highly selective permeability through the blood-brain barrier (BBB) is essential for brain disease treatment. In this research, we designed and prepared a novel target nanoplatform, that is, layered double hydroxide (LDH) nanoparticle conjugated with targeting peptide-ligand Angiopep-2 (Ang2) or rabies virus glycoprotein (RVG) via intermatrix bovine serum albumin for brain targeting. In vitro studies show that functionalization with the target ligand significantly increases the delivery efficiency of LDH nanoparticles to the brain endothelial (bEnd.3) cells and the transcytosis through the simulated BBB model, that is, bEnd.3 cell-constructed multilayer membrane. In vivo confocal neuroimaging of the rat's blood-retina area dynamically demonstrates that LDH nanoparticles modified with peptide ligands have shown a prolonged retention period within the retina vessel in comparison with the pristine LDH group. Moreover, Ang2-modified LDH nanoparticles are found to more specifically accumulate in the mouse brain than the control and RVG-modified LDH nanoparticles after 2 and 48 h intravenous injection. All these findings strongly suggest that Ang2-modified LDHs can serve as an effective targeting nanoplatform for brain disease treatment. A delivery platform with highly selective permeability through the blood-brain barrier (BBB) is essential for brain disease treatment. In this research, we designed and prepared a novel target nanoplatform, that is, layered double hydroxide (LDH) nanoparticle conjugated with targeting peptide-ligand Angiopep-2 (Ang2) or rabies virus glycoprotein (RVG) via intermatrix bovine serum albumin for brain targeting. In vitro studies show that functionalization with the target ligand significantly increases the delivery efficiency of LDH nanoparticles to the brain endothelial (bEnd.3) cells and the transcytosis through the simulated BBB model, that is, bEnd.3 cell-constructed multilayer membrane. In vivo confocal neuroimaging of the rat's blood-retina area dynamically demonstrates that LDH nanoparticles modified with peptide ligands have shown a prolonged retention period within the retina vessel in comparison with the pristine LDH group. Moreover, Ang2-modified LDH nanoparticles are found to more specifically accumulate in the mouse brain than the control and RVG-modified LDH nanoparticles after 2 and 48 h intravenous injection. All these findings strongly suggest that Ang2-modified LDHs can serve as an effective targeting nanoplatform for brain disease treatment. |
| Author | Li, Li Xu, Zhi Ping Henrich-Noack, Petra Zhang, Enqi Zuo, Huali Chen, Weiyu Cooper, Helen Qian, Yujin |
| Author_xml | – sequence: 1 givenname: Weiyu surname: Chen fullname: Chen, Weiyu – sequence: 2 givenname: Huali surname: Zuo fullname: Zuo, Huali – sequence: 3 givenname: Enqi surname: Zhang fullname: Zhang, Enqi organization: Otto-von-Guericke University , Magdeburg 39106 , Germany – sequence: 4 givenname: Li surname: Li fullname: Li, Li – sequence: 5 givenname: Petra surname: Henrich-Noack fullname: Henrich-Noack, Petra organization: Otto-von-Guericke University , Magdeburg 39106 , Germany – sequence: 6 givenname: Helen surname: Cooper fullname: Cooper, Helen – sequence: 7 givenname: Yujin surname: Qian fullname: Qian, Yujin – sequence: 8 givenname: Zhi Ping orcidid: 0000-0001-6070-5035 surname: Xu fullname: Xu, Zhi Ping |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29799186$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkDtPwzAUhS1URB-wMqKMLCl-5eERWkqRIljKHN3EN5WR6xQ7QYRfTySKxHQ-6Xw6w5mTiWsdEnLN6JJRzu6gDnAwy7yiMmXijMyYkjLOecIn_3hK5iG8U5oKTpMLMuUqU4rl6YzoBw_GRTvwe-yM20drtOYT_RBtoDbWdNChjqohKswenI43vas70zqw5nssChjQj7lu-8pitB20b7-MxugFXHsE35naYrgk5w3YgFenXJC3zeNutY2L16fn1X0Rg-Sqi3PGE12zikGDKddMq6ppBJMgIGtYqlPgQjHWSFSVQqkFMpEn2UiQ8TSv-YLc_u4effvRY-jKgwk1WgsO2z6UnMpEUKmoHNWbk9pXB9Tl0ZsD-KH8e4b_AM22aV8 |
| CitedBy_id | crossref_primary_10_1002_bmm2_70013 crossref_primary_10_1016_j_jconrel_2018_11_008 crossref_primary_10_1016_j_mattod_2020_11_015 crossref_primary_10_1039_D1NR00881A crossref_primary_10_3390_pharmaceutics14030672 crossref_primary_10_3390_electronics11162559 crossref_primary_10_1021_acsbiomaterials_8b01420 crossref_primary_10_1016_j_cclet_2021_12_033 crossref_primary_10_1002_adhm_202404857 crossref_primary_10_1002_adma_202208665 crossref_primary_10_1002_adma_202502375 crossref_primary_10_1016_j_jallcom_2020_156868 crossref_primary_10_1016_j_nano_2021_102369 crossref_primary_10_1016_j_ijpharm_2024_124962 crossref_primary_10_1016_j_nantod_2023_101788 crossref_primary_10_1016_j_biomaterials_2020_120461 crossref_primary_10_1002_smll_201900262 crossref_primary_10_3390_pharmaceutics13122045 crossref_primary_10_1021_acsomega_5c06491 crossref_primary_10_1016_j_apsb_2024_09_012 crossref_primary_10_1016_j_cis_2023_102869 crossref_primary_10_1016_j_addr_2023_115131 crossref_primary_10_1039_D4TB02476A crossref_primary_10_1016_j_jddst_2021_103026 crossref_primary_10_1002_adfm_202412705 crossref_primary_10_1016_j_clay_2019_105196 crossref_primary_10_1186_s12951_023_02008_9 crossref_primary_10_1016_j_ijpharm_2020_119921 crossref_primary_10_1140_epjp_s13360_022_02993_0 crossref_primary_10_1186_s12951_024_02405_8 crossref_primary_10_1208_s12249_018_1180_3 crossref_primary_10_1093_plphys_kiac430 crossref_primary_10_1002_advs_201901724 crossref_primary_10_1016_j_ccr_2024_216109 crossref_primary_10_3390_nano9101404 crossref_primary_10_1186_s12987_023_00493_6 crossref_primary_10_3389_fchem_2020_00732 crossref_primary_10_1016_j_addr_2022_114451 crossref_primary_10_1002_smo_20240052 crossref_primary_10_1186_s12951_021_01096_9 crossref_primary_10_3390_ijms23169361 crossref_primary_10_1016_j_ijbiomac_2025_143645 crossref_primary_10_3390_pharmaceutics15020413 crossref_primary_10_1016_j_jddst_2020_101636 crossref_primary_10_1093_plphys_kiab303 crossref_primary_10_1002_adfm_202425165 crossref_primary_10_3390_polym14040712 crossref_primary_10_3390_nano13061102 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1021/acsami.8b04613 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Engineering |
| EISSN | 1944-8252 |
| ExternalDocumentID | 29799186 |
| Genre | Journal Article |
| GroupedDBID | --- .K2 23M 4.4 53G 55A 5GY 5VS 5ZA 6J9 7~N AABXI AAHBH ABBLG ABJNI ABLBI ABMVS ABQRX ABUCX ACGFS ACS ADHLV AEESW AENEX AFEFF AHGAQ ALMA_UNASSIGNED_HOLDINGS AQSVZ BAANH CGR CUPRZ CUY CVF EBS ECM ED~ EIF EJD F5P GGK GNL IH9 JG~ NPM P2P RNS ROL UI2 VF5 VG9 W1F XKZ 7X8 |
| ID | FETCH-LOGICAL-a429t-8125dc1b1afe62d1d9bff314a3a7f16d6a23911f4e9b9e4d3e13857e4da7268c2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 59 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000436211500014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1944-8252 |
| IngestDate | Wed Oct 01 13:49:25 EDT 2025 Mon Jul 21 05:48:10 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 24 |
| Keywords | blood−brain barrier blood-retina targeting layered double hydroxide bovine serum albumin coating brain target peptide |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a429t-8125dc1b1afe62d1d9bff314a3a7f16d6a23911f4e9b9e4d3e13857e4da7268c2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0001-6070-5035 |
| PMID | 29799186 |
| PQID | 2045304904 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2045304904 pubmed_primary_29799186 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-06-20 |
| PublicationDateYYYYMMDD | 2018-06-20 |
| PublicationDate_xml | – month: 06 year: 2018 text: 2018-06-20 day: 20 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | ACS applied materials & interfaces |
| PublicationTitleAlternate | ACS Appl Mater Interfaces |
| PublicationYear | 2018 |
| SSID | ssj0063205 |
| Score | 2.4754012 |
| Snippet | A delivery platform with highly selective permeability through the blood-brain barrier (BBB) is essential for brain disease treatment. In this research, we... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 20326 |
| SubjectTerms | Animals Blood-Brain Barrier Brain Hydroxides Ligands Mice Nanoparticles Rats |
| Title | Brain Targeting Delivery Facilitated by Ligand-Functionalized Layered Double Hydroxide Nanoparticles |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29799186 https://www.proquest.com/docview/2045304904 |
| Volume | 10 |
| WOSCitedRecordID | wos000436211500014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA7qetCD78f6IoLXYPPYNj2Jr7KHddnDKntbkiaVwtKu21Wsv95J21UvgmAPoaQUSjKd-SbzMR9CFwIuBWGPxB7XRFhKiQokDMaCL9RerCu5t6de0O_L0SgcNAduRUOrXPjEylGbPHZn5JeubborCXniavpCnGqUq642EhrLqMUByjirDkZfVQSfs4rCCHm6IJAJsUXTRkYvVVw4gR2pXcNx_ju8rMJMtPnfD9xCGw3AxNe1RWyjJZvtoPUfbQd3kblxuhB4WJHAYQbf2YmjZ5Q4UnHdtdsarEvcS59VZkgEsa8-Mkw_4EFPlU7gEwP21hOLu6WZ5e-psRg8NaTgDdNuDz1G98PbLmnUFoiCmDQnEOk7JqaaqsT6zFAT6iThVCiugoT6xleMg2dMhA11aIXhlnLZCeBOBcyXMdtHK1me2UOENewFAC1DPQvZpqRKCGMCmnAbABrhpo3OF0s4Bmt2JQqV2fy1GH8vYhsd1PswntZtN8bMVSCp9I_-8PYxWgNkIx2ni3knqJXAv2xP0Wr8Nk-L2VllJjD2Bw-fJk_Ivw |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Brain+Targeting+Delivery+Facilitated+by+Ligand-Functionalized+Layered+Double+Hydroxide+Nanoparticles&rft.jtitle=ACS+applied+materials+%26+interfaces&rft.au=Chen%2C+Weiyu&rft.au=Zuo%2C+Huali&rft.au=Zhang%2C+Enqi&rft.au=Li%2C+Li&rft.date=2018-06-20&rft.eissn=1944-8252&rft.volume=10&rft.issue=24&rft.spage=20326&rft_id=info:doi/10.1021%2Facsami.8b04613&rft_id=info%3Apmid%2F29799186&rft_id=info%3Apmid%2F29799186&rft.externalDocID=29799186 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1944-8252&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1944-8252&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1944-8252&client=summon |